TA-65 does not increase telomere length during post-natal development in house sparrow chicks (Passer domesticus)

Telomeres, protective caps at the end of chromosomes, are often positively related to lifespan and are thought to be an important mechanism of organismal aging. To better understand the casual relationships between telomere length and longevity, it is essential to be able to experimentally manipulate telomere dynamics (length and loss rate). Previous studies suggest that exposure to TA-65, an extract from the Chinese root Astragalus membranaceus, activates telomerase, lengthens telomeres, increases the growth of keratin-based structures, and boosts the immune system in adults. However, telomere loss is expected to be greatest during early life but whether TA-65 has similar effects during this life stage is currently unknown. Here, we experimentally exposed free-living house sparrow (Passer domesticus) chicks to TA-65 during post-natal development and examined the effects on telomere length and loss, growth of keratin-based structures, and a measure of cellular immunity. Contrary to expectation, the growth of keratin-based structures was reduced in TA-65 chicks and in the second year of the study, chicks exposed to TA-65 experienced more telomere loss than controls. Thus, the effects of TA-65 on telomeres and keratin-based structures differ across life stages and future research will be necessary to determine the mechanisms underlying these age-specific effects.

A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study

TA-65 is a dietary supplement based on an improved formulation of a small molecule telomerase activator that was discovered in a systematic screening of natural product extracts from traditional Chinese medicines. This study summarizes the findings on telomere length (TL) changes from a randomized, double blind, placebo controlled study of TA-65 over a 1 year period. The study was conducted on 117 relatively healthy cytomegalovirus-positive subjects aged 53–87 years old. Subjects taking the low dose of TA-65 (250 U) significantly increased TL over the 12 months period (530 ± 180 bp; p = 0.005), whereas subjects in the placebo group significantly lost TL (290 ± 100 bp; p = 0.01). The high dose of TA-65 (1000 U) showed a trend of improvements in TL compared with that of the placebo group; however, the improvements did not reach statistical significance. TL changes in the low-dose group were similar for both median and 20th percentile TLs. The findings suggest that TA-65 can lengthen telomeres in a statistically and possibly clinically significant manner.